vegfa vascular endothelial growth factor a rna targeting via crispr cas13 technology to inhibit choroidal neovascularization cnv in neovascular age related macular degeneration namd clinical trial intelligence

A Phase 1, Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of HG202 High-fidelity CRISPR-Cas13 (hfCas13Y) RNA-targeting Therapy for Neovascular Age-related Macular Degeneration (nAMD)

HG202, developed by HuidaGene Therapeutics, represents a novel approach to treating nAMD through a one-time gene-editing therapy that aims to reduce the need for frequent anti-VEGF injections, which are the current standard of care. The potential to provide long-term efficacy with a single administration could significantly alleviate the burden on healthcare systems and improve patient quality of life. The nAMD market is substantial, with existing therapies facing limitations such as treatment resistance and the need for ongoing injections. If successful, HG202 could capture a significant share of this market, particularly among patients who do not respond adequately to current therapies. The trial's outcomes will be critical in determining the asset's commercial viability and positioning against established anti-VEGF therapies.

Matched by target_normalized: VEGFA (Vascular Endothelial Growth Factor A) - RNA-targeting via CRISPR/Cas13 technology to inhibit choroidal neovascularization (CNV) in neovascular Age-related Macular Degeneration (nAMD).